BRAF and non-small cell lung carcinoma: Overall, our analysis confirms and extends prior observations, demonstrating that NSCLC patients with BRAF Class II mutations have worse prognosis compared to those with Class I mutations, potentially due to the lack of effective targeted therapy options.